BCRX - BioCryst Pharmaceuticals, Inc. Debt to Book Capitalization Ratio
BioCryst focuses on developing therapies for individuals with orphan diseases, leveraging an ethical approach and an RSU system for its scientists. This price chart on GURU.Markets, where the indicator stands at 0.00, confirms the asset's dynamics. However, geopolitical conflicts are hindering component logistics, while the company's environmental policy is limited to standard waste control and office energy audits.
%20Debt%20to%20Net%20Assets%20Ratio&width=1200&height=400&colorIndex=0&v=mvouo2ve.rkk-7albim8&start=20220704&end=20261026&filename=GURU_Markets_-_BCRX_-_BioCryst_-_Debt-to-Net-Assets-Ratio "BioCryst - BCRX Debt to Book Capitalization Ratio (period 07/04/2022 - 10/26/2026) | 👁️GURU.Markets👁️")
Metric breakdowns and analytics for BioCryst Pharmaceuticals, Inc. (BCRX)
Company indicators for BioCryst (BCRX):
Stock Price BioCryst|BCRX - Analyst Consensus Forecast|Market Value BioCryst Corp|BCRX - Value Adjusted for Debt and Cash|Net Assets per Single Share BioCryst|BCRX - Company Net Assets|Market Capitalization to Book Value Ratio biocryst.com|BCRX - Company Total Assets|Total Debt to Equity Ratio BioCryst|BCRX - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital BioCryst Pharmaceuticals Inc|BCRX - Company Total Debt Obligations|Debt to Book Capitalization Ratio BioCryst Corp
Summary company analytics:BioCryst (BCRX)
This ratio reflects the sensitivity of the capital structure to the market value of assets, allowing for an assessment of the real debt load through the lens of daily exchange quotes. Analyzing the ratio of financial debt to book capitalization is critically important for BioCryst (BCRX), as geopolitical instability and the disruption of component supply chains increase the risk of capital volatility, turning this indicator into the primary marker of financial stability.
Who BioCryst competes with
Debts to Book Capitalization ARGX (argenx SE)|biontech.de - Debts to Book Capitalization|Debt to Book Capitalization Ratio ABIVAX (ABVX)|ADMA: Debt to Net Assets Ratio|PTGX (Protagonist Therapeutics Inc) - Debt to Book Capitalization Ratio|Immunovant Therapeutics (IMVT) - Debt to Book Value|KNSA (Kiniksa Pharmaceuticals) - Debts to Book Capitalization|Debts to Book Capitalization grifols.com (GRFS)|Adaptive Biotechnologies Corporation (ADPT) - Debt to Book Value|Debt to Net Assets Ratio Celldex Therapeutics Inc (CLDX)|Debts to Book Capitalization AUPH|Vera Corp - Debts to Net Assets|DNTH: Debt to Book Capitalization Ratio|PHVS: Debt to Book Value|ABCL (AbCellera Corp) - Debt to Book Capitalization Ratio|Debt to Book Value Tourmaline Bio Inc|PGEN (Intrexon) - Debt to Book Value|Debts to Book Capitalization PHAR|Debt to Book Capitalization Ratio Nektar Therapeutics NKTR|Debt to Book Value Ratio upstreambio.com (UPB)|ZBIO: Debts to Book Capitalization|Debts to Book Value Immunome Inc IMNM|GOSS - Debts to Book Capitalization|KALV - Debt to Book Capitalization Ratio|Septerna Inc - Debts to Book Capitalization|PVLA (pieris.com) - Debts to Net Assets|Debt to Book Capitalization Ratio SVRA (Savara)|Debts to Book Value Rigel Pharma|Debts to Book Capitalization ANAB (AnaptysBio Corp)|Debt to Book Value ATXS (Astria Corp)|Debt to Book Capitalization Ratio enGene Holdings Inc.|RAPT - Debt to Net Assets Ratio|JBIO (Aerovate) - Debt to Book Value|ACRS: Debts to Book Value|Kyverna - Debt to Book Capitalization Ratio|Debts to Net Assets Tiziana Life Sciences, Ltd.|Cabaletta Bio, Inc. (CABA) - Debt to Book Value|Debt to Book Capital ventyxbio.com|Debts to Book Capitalization Theratechnologies (THTX)|Debt to Book Capitalization Ratio Avalo Therapeutics, Inc. (AVTX)|Eledon - Debts to Book Capitalization|Agenus, Inc - Debt to Book Value|Debt to Book Capitalization Ratio Climb Bio Inc (CLYM)|Zura Bio Ltd (ZURA) - Debt to Net Assets Ratio|Debt to Book Value aTyr Pharma|ADAG (Adagene Inc.) - Debt to Book Value Ratio|Debt to Book Capitalization Ratio ImageneBio IMA|Debts to Book Capitalization Ratio Shattuck Therapeutics|Equillium, Inc. (EQ) - Debts to Book Capitalization|Debt to Net Assets Ratio connectbiopharm.com (CNTB)|Debts to Book Capitalization IMUX (Immunic)|Atara Biotherapeutics, Inc. - Debts to Book Capitalization|Debt to Book Capitalization Ratio InflaRx GmbH (IFRX)|XFOR: Debt to Net Assets Ratio|ACET (adicetbio.com) - Debt to Book Capitalization Ratio|Celularity (CELU) - Debt to Book Value|INMB (INmune Bio) - Debts to Book Capitalization|Debts to Book Capitalization Barinthus Biotherapeutics PLC (BRNS)|Kezar Life Sciences, Inc (KZR) - Debt to Book Value|Debt to Net Assets Ratio SAB Biotherapeutics Inc (SABS)|Debts to Book Capitalization AKTX|Enlivex Therapeutics Ltd - Debts to Net Assets|QTTB: Debt to Book Capitalization Ratio|GOVX: Debt to Book Value|EDSA (Edesa) - Debt to Book Capitalization Ratio|Debt to Book Value iBio Corporation|CARM (Carisma Therapeutics Inc) - Debt to Book Value|Debts to Book Capitalization XTLB|Debt to Book Capitalization Ratio Bolt Biotherapeutics BOLT|Debt to Book Value Ratio hcwbiologics.com (HCWB)|APVO: Debts to Book Capitalization|Debts to Book Value AIM ImmunoTech, Inc. AIM|ADTX - Debts to Book Capitalization|GRI - Debt to Book Capitalization Ratio|XORTX Therapeutics - Debts to Book Capitalization|HIND (Vyome Holdings Inc.) - Debts to Net Assets|Debt to Book Capitalization Ratio REVB (Revelation Bio)|Debts to Book Value Indaptus Corp|Debts to Book Capitalization SCNI (Scinai Immunotherapeutics)|Debt to Book Value CALI (calcimedica.com)|Debt to Book Capitalization Ratio Affimed N.V.|ALLK - Debt to Net Assets Ratio|HOOK (HOOKIPA) - Debt to Book Value|IGMS: Debts to Book Value|iTeos Therapeutics - Debt to Book Capitalization Ratio|Debts to Net Assets oceanbiomedical.com|TC BioPharm (TCBP) - Debt to Book Value|Debt to Book Capital Third Harmonic Bio Inc.